[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Psychedelic Medicine Market Insights, Forecast to 2029

December 2023 | 126 pages | ID: G6B6159B0773EN
QYResearch

US$ 4,900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report presents an overview of global market for Psychedelic Medicine market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Psychedelic Medicine, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Psychedelic Medicine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Psychedelic Medicine revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Psychedelic Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Psychedelic Medicine revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including COMPASS Pathways PLC, Pfizer, Eli Lilly, GlaxoSmithKline, Cybin Inc, Field Trip Health, ATAI Life Sciences, NUMINUS WELLNESS and MindMed, etc.

By Company
  • COMPASS Pathways PLC
  • Pfizer
  • Eli Lilly
  • GlaxoSmithKline
  • Cybin Inc
  • Field Trip Health
  • ATAI Life Sciences
  • NUMINUS WELLNESS
  • MindMed
  • HAVN Life Sciences
  • Seelos Therapeutics
  • Jannsen
  • Acadia Pharmaceuticals
  • Intellipharmaceutics
  • Revive Therapeutics
  • Mydecine Innovations Group
  • Red Light Holland
  • Braxia Scientific
  • Mind Cure Health
  • Entheon Biomedical
Segment by Type
  • Psilocybin
  • LSD
  • MDMA
  • DMT
  • Ketamine
  • Others
Segment by Application
  • Depressive Disorders
  • Post-Traumatic Stress Disorders
  • Substance Abuse Disorders
  • Obsessive Compulsive Disorders
  • Others
By Region
  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East, Africa, and Latin America
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA
Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Psychedelic Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Psychedelic Medicine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psychedelic Medicine revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW

1.1 Study Scope
1.2 Market Analysis by Type
  1.2.1 Global Psychedelic Medicine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  1.2.2 Psilocybin
  1.2.3 LSD
  1.2.4 MDMA
  1.2.5 DMT
  1.2.6 Ketamine
  1.2.7 Others
1.3 Market by Application
  1.3.1 Global Psychedelic Medicine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  1.3.2 Depressive Disorders
  1.3.3 Post-Traumatic Stress Disorders
  1.3.4 Substance Abuse Disorders
  1.3.5 Obsessive Compulsive Disorders
  1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Psychedelic Medicine Market Perspective (2018-2029)
2.2 Global Psychedelic Medicine Growth Trends by Region
  2.2.1 Psychedelic Medicine Market Size by Region: 2018 VS 2022 VS 2029
  2.2.2 Psychedelic Medicine Historic Market Size by Region (2018-2023)
  2.2.3 Psychedelic Medicine Forecasted Market Size by Region (2024-2029)
2.3 Psychedelic Medicine Market Dynamics
  2.3.1 Psychedelic Medicine Industry Trends
  2.3.2 Psychedelic Medicine Market Drivers
  2.3.3 Psychedelic Medicine Market Challenges
  2.3.4 Psychedelic Medicine Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Revenue Psychedelic Medicine by Players
  3.1.1 Global Psychedelic Medicine Revenue by Players (2018-2023)
  3.1.2 Global Psychedelic Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Psychedelic Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Psychedelic Medicine, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Psychedelic Medicine Market Concentration Ratio
  3.4.1 Global Psychedelic Medicine Market Concentration Ratio (CR5 and HHI)
  3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Medicine Revenue in 2022
3.5 Global Key Players of Psychedelic Medicine Head office and Area Served
3.6 Global Key Players of Psychedelic Medicine, Product and Application
3.7 Global Key Players of Psychedelic Medicine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans

4 PSYCHEDELIC MEDICINE BREAKDOWN DATA BY TYPE

4.1 Global Psychedelic Medicine Historic Market Size by Type (2018-2023)
4.2 Global Psychedelic Medicine Forecasted Market Size by Type (2024-2029)

5 PSYCHEDELIC MEDICINE BREAKDOWN DATA BY APPLICATION

5.1 Global Psychedelic Medicine Historic Market Size by Application (2018-2023)
5.2 Global Psychedelic Medicine Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Psychedelic Medicine Market Size (2018-2029)
6.2 North America Psychedelic Medicine Market Size by Type
  6.2.1 North America Psychedelic Medicine Market Size by Type (2018-2023)
  6.2.2 North America Psychedelic Medicine Market Size by Type (2024-2029)
  6.2.3 North America Psychedelic Medicine Market Share by Type (2018-2029)
6.3 North America Psychedelic Medicine Market Size by Application
  6.3.1 North America Psychedelic Medicine Market Size by Application (2018-2023)
  6.3.2 North America Psychedelic Medicine Market Size by Application (2024-2029)
  6.3.3 North America Psychedelic Medicine Market Share by Application (2018-2029)
6.4 North America Psychedelic Medicine Market Size by Country
  6.4.1 North America Psychedelic Medicine Market Size by Country: 2018 VS 2022 VS 2029
  6.4.2 North America Psychedelic Medicine Market Size by Country (2018-2023)
  6.4.3 North America Psychedelic Medicine Market Size by Country (2024-2029)
  6.4.4 United States
  6.4.5 Canada

7 EUROPE

7.1 Europe Psychedelic Medicine Market Size (2018-2029)
7.2 Europe Psychedelic Medicine Market Size by Type
  7.2.1 Europe Psychedelic Medicine Market Size by Type (2018-2023)
  7.2.2 Europe Psychedelic Medicine Market Size by Type (2024-2029)
  7.2.3 Europe Psychedelic Medicine Market Share by Type (2018-2029)
7.3 Europe Psychedelic Medicine Market Size by Application
  7.3.1 Europe Psychedelic Medicine Market Size by Application (2018-2023)
  7.3.2 Europe Psychedelic Medicine Market Size by Application (2024-2029)
  7.3.3 Europe Psychedelic Medicine Market Share by Application (2018-2029)
7.4 Europe Psychedelic Medicine Market Size by Country
  7.4.1 Europe Psychedelic Medicine Market Size by Country: 2018 VS 2022 VS 2029
  7.4.2 Europe Psychedelic Medicine Market Size by Country (2018-2023)
  7.4.3 Europe Psychedelic Medicine Market Size by Country (2024-2029)
  7.4.3 Germany
  7.4.4 France
  7.4.5 U.K.
  7.4.6 Italy
  7.4.7 Russia
  7.4.8 Nordic Countries

8 CHINA

8.1 China Psychedelic Medicine Market Size (2018-2029)
8.2 China Psychedelic Medicine Market Size by Type
  8.2.1 China Psychedelic Medicine Market Size by Type (2018-2023)
  8.2.2 China Psychedelic Medicine Market Size by Type (2024-2029)
  8.2.3 China Psychedelic Medicine Market Share by Type (2018-2029)
8.3 China Psychedelic Medicine Market Size by Application
  8.3.1 China Psychedelic Medicine Market Size by Application (2018-2023)
  8.3.2 China Psychedelic Medicine Market Size by Application (2024-2029)
  8.3.3 China Psychedelic Medicine Market Share by Application (2018-2029)

9 ASIA (EXCLUDING CHINA)

9.1 Asia Psychedelic Medicine Market Size (2018-2029)
9.2 Asia Psychedelic Medicine Market Size by Type
  9.2.1 Asia Psychedelic Medicine Market Size by Type (2018-2023)
  9.2.2 Asia Psychedelic Medicine Market Size by Type (2024-2029)
  9.2.3 Asia Psychedelic Medicine Market Share by Type (2018-2029)
9.3 Asia Psychedelic Medicine Market Size by Application
  9.3.1 Asia Psychedelic Medicine Market Size by Application (2018-2023)
  9.3.2 Asia Psychedelic Medicine Market Size by Application (2024-2029)
  9.3.3 Asia Psychedelic Medicine Market Share by Application (2018-2029)
9.4 Asia Psychedelic Medicine Market Size by Region
  9.4.1 Asia Psychedelic Medicine Market Size by Region: 2018 VS 2022 VS 2029
  9.4.2 Asia Psychedelic Medicine Market Size by Region (2018-2023)
  9.4.3 Asia Psychedelic Medicine Market Size by Region (2024-2029)
  9.4.4 Japan
  9.4.5 South Korea
  9.4.6 China Taiwan
  9.4.7 Southeast Asia
  9.4.8 India
  9.4.9 Australia

10 MIDDLE EAST, AFRICA, AND LATIN AMERICA

10.1 Middle East, Africa, and Latin America Psychedelic Medicine Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Type
  10.2.1 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Type (2018-2023)
  10.2.2 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Type (2024-2029)
  10.2.3 Middle East, Africa, and Latin America Psychedelic Medicine Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Application
  10.3.1 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Application (2018-2023)
  10.3.2 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Application (2024-2029)
  10.3.3 Middle East, Africa, and Latin America Psychedelic Medicine Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Country
  10.4.1 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Country: 2018 VS 2022 VS 2029
  10.4.2 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Country (2018-2023)
  10.4.3 Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Country (2024-2029)
  10.4.4 Brazil
  10.4.5 Mexico
  10.4.6 Turkey
  10.4.7 Saudi Arabia
  10.4.8 Israel
  10.4.9 GCC Countries

11 KEY PLAYERS PROFILES

11.1 COMPASS Pathways PLC
  11.1.1 COMPASS Pathways PLC Company Details
  11.1.2 COMPASS Pathways PLC Business Overview
  11.1.3 COMPASS Pathways PLC Psychedelic Medicine Introduction
  11.1.4 COMPASS Pathways PLC Revenue in Psychedelic Medicine Business (2018-2023)
  11.1.5 COMPASS Pathways PLC Recent Developments
11.2 Pfizer
  11.2.1 Pfizer Company Details
  11.2.2 Pfizer Business Overview
  11.2.3 Pfizer Psychedelic Medicine Introduction
  11.2.4 Pfizer Revenue in Psychedelic Medicine Business (2018-2023)
  11.2.5 Pfizer Recent Developments
11.3 Eli Lilly
  11.3.1 Eli Lilly Company Details
  11.3.2 Eli Lilly Business Overview
  11.3.3 Eli Lilly Psychedelic Medicine Introduction
  11.3.4 Eli Lilly Revenue in Psychedelic Medicine Business (2018-2023)
  11.3.5 Eli Lilly Recent Developments
11.4 GlaxoSmithKline
  11.4.1 GlaxoSmithKline Company Details
  11.4.2 GlaxoSmithKline Business Overview
  11.4.3 GlaxoSmithKline Psychedelic Medicine Introduction
  11.4.4 GlaxoSmithKline Revenue in Psychedelic Medicine Business (2018-2023)
  11.4.5 GlaxoSmithKline Recent Developments
11.5 Cybin Inc
  11.5.1 Cybin Inc Company Details
  11.5.2 Cybin Inc Business Overview
  11.5.3 Cybin Inc Psychedelic Medicine Introduction
  11.5.4 Cybin Inc Revenue in Psychedelic Medicine Business (2018-2023)
  11.5.5 Cybin Inc Recent Developments
11.6 Field Trip Health
  11.6.1 Field Trip Health Company Details
  11.6.2 Field Trip Health Business Overview
  11.6.3 Field Trip Health Psychedelic Medicine Introduction
  11.6.4 Field Trip Health Revenue in Psychedelic Medicine Business (2018-2023)
  11.6.5 Field Trip Health Recent Developments
11.7 ATAI Life Sciences
  11.7.1 ATAI Life Sciences Company Details
  11.7.2 ATAI Life Sciences Business Overview
  11.7.3 ATAI Life Sciences Psychedelic Medicine Introduction
  11.7.4 ATAI Life Sciences Revenue in Psychedelic Medicine Business (2018-2023)
  11.7.5 ATAI Life Sciences Recent Developments
11.8 NUMINUS WELLNESS
  11.8.1 NUMINUS WELLNESS Company Details
  11.8.2 NUMINUS WELLNESS Business Overview
  11.8.3 NUMINUS WELLNESS Psychedelic Medicine Introduction
  11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Medicine Business (2018-2023)
  11.8.5 NUMINUS WELLNESS Recent Developments
11.9 MindMed
  11.9.1 MindMed Company Details
  11.9.2 MindMed Business Overview
  11.9.3 MindMed Psychedelic Medicine Introduction
  11.9.4 MindMed Revenue in Psychedelic Medicine Business (2018-2023)
  11.9.5 MindMed Recent Developments
11.10 HAVN Life Sciences
  11.10.1 HAVN Life Sciences Company Details
  11.10.2 HAVN Life Sciences Business Overview
  11.10.3 HAVN Life Sciences Psychedelic Medicine Introduction
  11.10.4 HAVN Life Sciences Revenue in Psychedelic Medicine Business (2018-2023)
  11.10.5 HAVN Life Sciences Recent Developments
11.11 Seelos Therapeutics
  11.11.1 Seelos Therapeutics Company Details
  11.11.2 Seelos Therapeutics Business Overview
  11.11.3 Seelos Therapeutics Psychedelic Medicine Introduction
  11.11.4 Seelos Therapeutics Revenue in Psychedelic Medicine Business (2018-2023)
  11.11.5 Seelos Therapeutics Recent Developments
11.12 Jannsen
  11.12.1 Jannsen Company Details
  11.12.2 Jannsen Business Overview
  11.12.3 Jannsen Psychedelic Medicine Introduction
  11.12.4 Jannsen Revenue in Psychedelic Medicine Business (2018-2023)
  11.12.5 Jannsen Recent Developments
11.13 Acadia Pharmaceuticals
  11.13.1 Acadia Pharmaceuticals Company Details
  11.13.2 Acadia Pharmaceuticals Business Overview
  11.13.3 Acadia Pharmaceuticals Psychedelic Medicine Introduction
  11.13.4 Acadia Pharmaceuticals Revenue in Psychedelic Medicine Business (2018-2023)
  11.13.5 Acadia Pharmaceuticals Recent Developments
11.14 Intellipharmaceutics
  11.14.1 Intellipharmaceutics Company Details
  11.14.2 Intellipharmaceutics Business Overview
  11.14.3 Intellipharmaceutics Psychedelic Medicine Introduction
  11.14.4 Intellipharmaceutics Revenue in Psychedelic Medicine Business (2018-2023)
  11.14.5 Intellipharmaceutics Recent Developments
11.15 Revive Therapeutics
  11.15.1 Revive Therapeutics Company Details
  11.15.2 Revive Therapeutics Business Overview
  11.15.3 Revive Therapeutics Psychedelic Medicine Introduction
  11.15.4 Revive Therapeutics Revenue in Psychedelic Medicine Business (2018-2023)
  11.15.5 Revive Therapeutics Recent Developments
11.16 Mydecine Innovations Group
  11.16.1 Mydecine Innovations Group Company Details
  11.16.2 Mydecine Innovations Group Business Overview
  11.16.3 Mydecine Innovations Group Psychedelic Medicine Introduction
  11.16.4 Mydecine Innovations Group Revenue in Psychedelic Medicine Business (2018-2023)
  11.16.5 Mydecine Innovations Group Recent Developments
11.17 Red Light Holland
  11.17.1 Red Light Holland Company Details
  11.17.2 Red Light Holland Business Overview
  11.17.3 Red Light Holland Psychedelic Medicine Introduction
  11.17.4 Red Light Holland Revenue in Psychedelic Medicine Business (2018-2023)
  11.17.5 Red Light Holland Recent Developments
11.18 Braxia Scientific
  11.18.1 Braxia Scientific Company Details
  11.18.2 Braxia Scientific Business Overview
  11.18.3 Braxia Scientific Psychedelic Medicine Introduction
  11.18.4 Braxia Scientific Revenue in Psychedelic Medicine Business (2018-2023)
  11.18.5 Braxia Scientific Recent Developments
11.19 Mind Cure Health
  11.19.1 Mind Cure Health Company Details
  11.19.2 Mind Cure Health Business Overview
  11.19.3 Mind Cure Health Psychedelic Medicine Introduction
  11.19.4 Mind Cure Health Revenue in Psychedelic Medicine Business (2018-2023)
  11.19.5 Mind Cure Health Recent Developments
11.20 Entheon Biomedical
  11.20.1 Entheon Biomedical Company Details
  11.20.2 Entheon Biomedical Business Overview
  11.20.3 Entheon Biomedical Psychedelic Medicine Introduction
  11.20.4 Entheon Biomedical Revenue in Psychedelic Medicine Business (2018-2023)
  11.20.5 Entheon Biomedical Recent Developments

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology
  13.1.1 Methodology/Research Approach
  13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES

Table 1. Global Psychedelic Medicine Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Psilocybin
Table 3. Key Players of LSD
Table 4. Key Players of MDMA
Table 5. Key Players of DMT
Table 6. Key Players of Ketamine
Table 7. Key Players of Others
Table 8. Global Psychedelic Medicine Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 9. Global Psychedelic Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Psychedelic Medicine Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Psychedelic Medicine Market Share by Region (2018-2023)
Table 12. Global Psychedelic Medicine Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 13. Global Psychedelic Medicine Market Share by Region (2024-2029)
Table 14. Psychedelic Medicine Market Trends
Table 15. Psychedelic Medicine Market Drivers
Table 16. Psychedelic Medicine Market Challenges
Table 17. Psychedelic Medicine Market Restraints
Table 18. Global Psychedelic Medicine Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Psychedelic Medicine Revenue Share by Players (2018-2023)
Table 20. Global Top Psychedelic Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Medicine as of 2022)
Table 21. Global Psychedelic Medicine Industry Ranking 2021 VS 2022 VS 2023
Table 22. Global 5 Largest Players Market Share by Psychedelic Medicine Revenue (CR5 and HHI) & (2018-2023)
Table 23. Global Key Players of Psychedelic Medicine, Headquarters and Area Served
Table 24. Global Key Players of Psychedelic Medicine, Product and Application
Table 25. Global Key Players of Psychedelic Medicine, Product and Application
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Psychedelic Medicine Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Psychedelic Medicine Revenue Market Share by Type (2018-2023)
Table 29. Global Psychedelic Medicine Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 30. Global Psychedelic Medicine Revenue Market Share by Type (2024-2029)
Table 31. Global Psychedelic Medicine Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Psychedelic Medicine Revenue Share by Application (2018-2023)
Table 33. Global Psychedelic Medicine Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 34. Global Psychedelic Medicine Revenue Share by Application (2024-2029)
Table 35. North America Psychedelic Medicine Market Size by Type (2018-2023) & (US$ Million)
Table 36. North America Psychedelic Medicine Market Size by Type (2024-2029) & (US$ Million)
Table 37. North America Psychedelic Medicine Market Size by Application (2018-2023) & (US$ Million)
Table 38. North America Psychedelic Medicine Market Size by Application (2024-2029) & (US$ Million)
Table 39. North America Psychedelic Medicine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 40. North America Psychedelic Medicine Market Size by Country (2018-2023) & (US$ Million)
Table 41. North America Psychedelic Medicine Market Size by Country (2024-2029) & (US$ Million)
Table 42. Europe Psychedelic Medicine Market Size by Type (2018-2023) & (US$ Million)
Table 43. Europe Psychedelic Medicine Market Size by Type (2024-2029) & (US$ Million)
Table 44. Europe Psychedelic Medicine Market Size by Application (2018-2023) & (US$ Million)
Table 45. Europe Psychedelic Medicine Market Size by Application (2024-2029) & (US$ Million)
Table 46. Europe Psychedelic Medicine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Europe Psychedelic Medicine Market Size by Country (2018-2023) & (US$ Million)
Table 48. Europe Psychedelic Medicine Market Size by Country (2024-2029) & (US$ Million)
Table 49. China Psychedelic Medicine Market Size by Type (2018-2023) & (US$ Million)
Table 50. China Psychedelic Medicine Market Size by Type (2024-2029) & (US$ Million)
Table 51. China Psychedelic Medicine Market Size by Application (2018-2023) & (US$ Million)
Table 52. China Psychedelic Medicine Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Psychedelic Medicine Market Size by Type (2018-2023) & (US$ Million)
Table 54. Asia Psychedelic Medicine Market Size by Type (2024-2029) & (US$ Million)
Table 55. Asia Psychedelic Medicine Market Size by Application (2018-2023) & (US$ Million)
Table 56. Asia Psychedelic Medicine Market Size by Application (2024-2029) & (US$ Million)
Table 57. Asia Psychedelic Medicine Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 58. Asia Psychedelic Medicine Market Size by Region (2018-2023) & (US$ Million)
Table 59. Asia Psychedelic Medicine Market Size by Region (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Type (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Type (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Application (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Application (2024-2029) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Psychedelic Medicine Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 65. Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Country (2018-2023) & (US$ Million)
Table 66. Middle East, Africa, and Latin America Psychedelic Medicine Market Size by Country (2024-2029) & (US$ Million)
Table 67. COMPASS Pathways PLC Company Details
Table 68. COMPASS Pathways PLC Business Overview
Table 69. COMPASS Pathways PLC Psychedelic Medicine Product
Table 70. COMPASS Pathways PLC Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 71. COMPASS Pathways PLC Recent Developments
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Psychedelic Medicine Product
Table 75. Pfizer Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 76. Pfizer Recent Developments
Table 77. Eli Lilly Company Details
Table 78. Eli Lilly Business Overview
Table 79. Eli Lilly Psychedelic Medicine Product
Table 80. Eli Lilly Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 81. Eli Lilly Recent Developments
Table 82. GlaxoSmithKline Company Details
Table 83. GlaxoSmithKline Business Overview
Table 84. GlaxoSmithKline Psychedelic Medicine Product
Table 85. GlaxoSmithKline Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 86. GlaxoSmithKline Recent Developments
Table 87. Cybin Inc Company Details
Table 88. Cybin Inc Business Overview
Table 89. Cybin Inc Psychedelic Medicine Product
Table 90. Cybin Inc Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 91. Cybin Inc Recent Developments
Table 92. Field Trip Health Company Details
Table 93. Field Trip Health Business Overview
Table 94. Field Trip Health Psychedelic Medicine Product
Table 95. Field Trip Health Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 96. Field Trip Health Recent Developments
Table 97. ATAI Life Sciences Company Details
Table 98. ATAI Life Sciences Business Overview
Table 99. ATAI Life Sciences Psychedelic Medicine Product
Table 100. ATAI Life Sciences Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 101. ATAI Life Sciences Recent Developments
Table 102. NUMINUS WELLNESS Company Details
Table 103. NUMINUS WELLNESS Business Overview
Table 104. NUMINUS WELLNESS Psychedelic Medicine Product
Table 105. NUMINUS WELLNESS Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 106. NUMINUS WELLNESS Recent Developments
Table 107. MindMed Company Details
Table 108. MindMed Business Overview
Table 109. MindMed Psychedelic Medicine Product
Table 110. MindMed Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 111. MindMed Recent Developments
Table 112. HAVN Life Sciences Company Details
Table 113. HAVN Life Sciences Business Overview
Table 114. HAVN Life Sciences Psychedelic Medicine Product
Table 115. HAVN Life Sciences Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 116. HAVN Life Sciences Recent Developments
Table 117. Seelos Therapeutics Company Details
Table 118. Seelos Therapeutics Business Overview
Table 119. Seelos Therapeutics Psychedelic Medicine Product
Table 120. Seelos Therapeutics Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 121. Seelos Therapeutics Recent Developments
Table 122. Jannsen Company Details
Table 123. Jannsen Business Overview
Table 124. Jannsen Psychedelic Medicine Product
Table 125. Jannsen Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 126. Jannsen Recent Developments
Table 127. Acadia Pharmaceuticals Company Details
Table 128. Acadia Pharmaceuticals Business Overview
Table 129. Acadia Pharmaceuticals Psychedelic Medicine Product
Table 130. Acadia Pharmaceuticals Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 131. Acadia Pharmaceuticals Recent Developments
Table 132. Intellipharmaceutics Company Details
Table 133. Intellipharmaceutics Business Overview
Table 134. Intellipharmaceutics Psychedelic Medicine Product
Table 135. Intellipharmaceutics Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 136. Intellipharmaceutics Recent Developments
Table 137. Revive Therapeutics Company Details
Table 138. Revive Therapeutics Business Overview
Table 139. Revive Therapeutics Psychedelic Medicine Product
Table 140. Revive Therapeutics Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 141. Revive Therapeutics Recent Developments
Table 142. Mydecine Innovations Group Company Details
Table 143. Mydecine Innovations Group Business Overview
Table 144. Mydecine Innovations Group Psychedelic Medicine Product
Table 145. Mydecine Innovations Group Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 146. Mydecine Innovations Group Recent Developments
Table 147. Red Light Holland Company Details
Table 148. Red Light Holland Business Overview
Table 149. Red Light Holland Psychedelic Medicine Product
Table 150. Red Light Holland Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 151. Red Light Holland Recent Developments
Table 152. Braxia Scientific Company Details
Table 153. Braxia Scientific Business Overview
Table 154. Braxia Scientific Psychedelic Medicine Product
Table 155. Braxia Scientific Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 156. Braxia Scientific Recent Developments
Table 157. Mind Cure Health Company Details
Table 158. Mind Cure Health Business Overview
Table 159. Mind Cure Health Psychedelic Medicine Product
Table 160. Mind Cure Health Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 161. Mind Cure Health Recent Developments
Table 162. Entheon Biomedical Company Details
Table 163. Entheon Biomedical Business Overview
Table 164. Entheon Biomedical Psychedelic Medicine Product
Table 165. Entheon Biomedical Revenue in Psychedelic Medicine Business (2018-2023) & (US$ Million)
Table 166. Entheon Biomedical Recent Developments
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources

LIST OF FIGURES

Figure 1. Global Psychedelic Medicine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Psychedelic Medicine Market Share by Type: 2022 VS 2029
Figure 3. Psilocybin Features
Figure 4. LSD Features
Figure 5. MDMA Features
Figure 6. DMT Features
Figure 7. Ketamine Features
Figure 8. Others Features
Figure 9. Global Psychedelic Medicine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 10. Global Psychedelic Medicine Market Share by Application: 2022 VS 2029
Figure 11. Depressive Disorders Case Studies
Figure 12. Post-Traumatic Stress Disorders Case Studies
Figure 13. Substance Abuse Disorders Case Studies
Figure 14. Obsessive Compulsive Disorders Case Studies
Figure 15. Others Case Studies
Figure 16. Psychedelic Medicine Report Years Considered
Figure 17. Global Psychedelic Medicine Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 18. Global Psychedelic Medicine Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 19. Global Psychedelic Medicine Market Share by Region: 2022 VS 2029
Figure 20. Global Psychedelic Medicine Market Share by Players in 2022
Figure 21. Global Top Psychedelic Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Medicine as of 2022)
Figure 22. The Top 10 and 5 Players Market Share by Psychedelic Medicine Revenue in 2022
Figure 23. North America Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. North America Psychedelic Medicine Market Share by Type (2018-2029)
Figure 25. North America Psychedelic Medicine Market Share by Application (2018-2029)
Figure 26. North America Psychedelic Medicine Market Share by Country (2018-2029)
Figure 27. United States Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Psychedelic Medicine Market Size YoY (2018-2029) & (US$ Million)
Figure 30. Europe Psychedelic Medicine Market Share by Type (2018-2029)
Figure 31. Europe Psychedelic Medicine Market Share by Application (2018-2029)
Figure 32. Europe Psychedelic Medicine Market Share by Country (2018-2029)
Figure 33. Germany Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. France Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. U.K. Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Italy Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Russia Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Nordic Countries Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. China Psychedelic Medicine Market Size YoY (2018-2029) & (US$ Million)
Figure 40. China Psychedelic Medicine Market Share by Type (2018-2029)
Figure 41. China Psychedelic Medicine Market Share by Application (2018-2029)
Figure 42. Asia Psychedelic Medicine Market Size YoY (2018-2029) & (US$ Million)
Figure 43. Asia Psychedelic Medicine Market Share by Type (2018-2029)
Figure 44. Asia Psychedelic Medicine Market Share by Application (2018-2029)
Figure 45. Asia Psychedelic Medicine Market Share by Region (2018-2029)
Figure 46. Japan Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. South Korea Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. China Taiwan Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. India Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Australia Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Middle East, Africa, and Latin America Psychedelic Medicine Market Size YoY (2018-2029) & (US$ Million)
Figure 53. Middle East, Africa, and Latin America Psychedelic Medicine Market Share by Type (2018-2029)
Figure 54. Middle East, Africa, and Latin America Psychedelic Medicine Market Share by Application (2018-2029)
Figure 55. Middle East, Africa, and Latin America Psychedelic Medicine Market Share by Country (2018-2029)
Figure 56. Brazil Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Mexico Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Turkey Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. Israel Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 61. GCC Countries Psychedelic Medicine Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 62. COMPASS Pathways PLC Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 63. Pfizer Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 64. Eli Lilly Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 66. Cybin Inc Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 67. Field Trip Health Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 68. ATAI Life Sciences Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 69. NUMINUS WELLNESS Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 70. MindMed Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 71. HAVN Life Sciences Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 72. Seelos Therapeutics Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 73. Jannsen Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 74. Acadia Pharmaceuticals Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 75. Intellipharmaceutics Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 76. Revive Therapeutics Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 77. Mydecine Innovations Group Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 78. Red Light Holland Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 79. Braxia Scientific Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 80. Mind Cure Health Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 81. Entheon Biomedical Revenue Growth Rate in Psychedelic Medicine Business (2018-2023)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed


More Publications